சிறப்பு தோப்பிக்ஷ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சிறப்பு தோப்பிக்ஷ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சிறப்பு தோப்பிக்ஷ Today - Breaking & Trending Today

Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers


Share this article
Share this article
EXTON, Pa., April 7, 2021 /PRNewswire/  Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the United States to track the impact of the COVID-19 pandemic on their practice operations, personal concerns, interaction with the pharmaceutical industry, and outlook for the near term. In all, Spherix collected feedback from more than 4,000 respondents via online survey, and the culmination of the report series,
Special Topix™: Multi-Specialty Impact of COVID-19 (US),
 was released last week – highlighting the evolution of the past year s events.
The 16
th wave, which is based on the responses of 267 US specialists surveyed on March 12, 2021, provides a unique year-over-year view of the impact of COVID-19. Here s where things stand today: ....

United States , Genentech Ocrevus , Kristen Henn , Novarti Kesimpta , American College Of Rheumatology , Centers For Disease Control , American Medical Association , American Society Of Nephrology , Business Development , Special Topix , Multi Specialty Impact , Disease Control , President Biden , President Trump , American College , American Society , Fraser Healthcare , Global Insights , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டன் கோழி , அமெரிக்கன் கல்லூரி ஆஃப் வாத நோய் , மையங்கள் க்கு நோய் கட்டுப்பாடு , அமெரிக்கன் மருத்துவ சங்கம் , அமெரிக்கன் சமூகம் ஆஃப் நெப்ராலஜி , வணிக வளர்ச்சி , சிறப்பு தோப்பிக்ஷ ,

Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?


Share this article
Share this article
EXTON, Pa., Feb. 10, 2021 /PRNewswire/  Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla.
1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb s acquisition of Celgene, considering future regulatory conflicts with BMS pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla.
Amgen s purchase of Otezla strengthens the company s long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix s ....

Novarti Cosentyx , Eli Lilly Taltz , Bob Bradway , Kristen Henn , Eli Lilly , Bristol Myers Squibb , Abbvie Skyrizi , Dermatologic Siliq , Janssen Tremfya , Our Services , Amgen Inc , Business Development , Realtime Dynamix , Ortho Dermatologic Siliq , Sun Dermatology , Special Topix , Multi Specialty Impact , Realworld Dynamix , Will Amgen , Time Dynamix , World Dynamix , Global Insights , Earnings Conference Call , Myers Squibb Announces Positive Topline Results , Second Pivotal Phase , Study Showing Superiority ,